Aventera Antibodies is developing a first-in-class precision immunotherapy against invasive Group A Streptococcal disease.
Aventera Antibodies has raised $1.6M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in April 2026.
Aventera Antibodies's investors include LU Ventures.
Aventera Antibodies is headquartered in Skane, Sweden.
Aventera Antibodies is developing a first-in-class precision immunotherapy against invasive Group A Streptococcal disease.
Aventera Antibodies is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aventera Antibodies — Funding & Investors." VCBacked, April 28, 2026, https://www.vcbacked.co/company/aventera-antibodies. Accessed August 5, 2026.
VCBacked. (2026). Aventera Antibodies — Funding & Investors. Retrieved August 5, 2026, from https://www.vcbacked.co/company/aventera-antibodies
{{cite web |title=Aventera Antibodies — Funding & Investors |url=https://www.vcbacked.co/company/aventera-antibodies |website=VCBacked |access-date=August 5, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated